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Abstract
Background: Sarcopenia, a loss of muscle strength and mass, has serious implications for older adults. Some risk
factors for sarcopenia are well established. The role of other factors such as alcohol consumption is less certain.
The main aim of this study was to explore the relationship between sarcopenia and alcohol consumption in
people over 65 years old.
Methods: Four electronic databases were searched to identify potentially relevant papers. Demographics and
information on sarcopenia and alcohol consumption were extracted from relevant papers. The relationship
between sarcopenia and alcohol consumption was described using odds ratios (ORs).
Results: Of 214 papers identified as potentially relevant, 13 were ultimately included in the meta-analyses. The
papers provided data from 13,155 participants. The OR (95 % CI) for sarcopenia among alcohol drinkers was 0.67
(0.54–0.83) for males, 0.89 (0.73–1.08) for females, and 0.77 (0.67–0.88) for the overall population.
Conclusions: The results of this meta-analysis do not support alcohol consumption as a risk factor for sarcopenia.
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Background
Although old age is not a disease, many diseases and
syndromes are more prevalent among older adults. As
the proportion of older adults is increasing, an under-
standing of age-related diseases and syndromes is crit-
ical. One syndrome particularly common among older
adults is sarcopenia [1]. Described by the European
Working Group on Sarcopenia in Older People (EWG-
SOP) as a loss of muscle mass and strength and de-
creased physical performance, sarcopenia is associated
with untoward outcomes such as disability, falls, and
mortality [2]. Although deterioration of muscle and
functional limitations have many causes and accompany
natural aging, they could be accelerated by modifiable
behavioral factors such as inactivity, undernutrition,
smoking, and alcohol consumption. The possible role of
alcohol consumption is of particular interest as it is
associated with a number of pathologies, including alco-
holic liver disease, pancreatic disease, neurological prob-
lems, cancer, and immunosuppression [3]. Ethanol
impairs skeletal muscle protein synthesis and muscle au-
tophagy is increased by ethanol exposure [4]. Alcohol
consumption is associated with cachexia [5]. Whether,
however, alcohol consumption is a risk factor for sarco-
penia is unclear. Although individual risk factors do not
work independently, the role of alcohol consumption as
a risk factor for sarcopenia should be clarified. The main
objective of this study was to explore relationships be-
tween sarcopenia and alcohol consumption in people
over 65 years of age. Following the recommendation of
the Cochrane Handbook for Systematic Reviews [6], we
pursued this objective by calculating odds ratios ORs.
The OR compares the relative odds of an outcome oc-
curring (in our case sarcopenia) based on exposure to a
variable of interest (in our case alcohol). In our study an
OR greater than 1 would suggest that sarcopenia is asso-
ciated with higher odds of developing sarcopenia and an
OR less than 1 would suggest that sarcopenia is associ-
ated with lower odds of having sarcopenia.
Methods
This review included cross-sectional studies and data
from baselines of longitudinal cohort studies. For the
* Correspondence: steffl@ftvs.cuni.cz
1Department of Physiology and Biochemistry, Faculty of Physical Education
and Sport, Charles University Prague, Prague, Czech Republic
Full list of author information is available at the end of the article
© 2016 Steffl et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Steffl et al. BMC Geriatrics  (2016) 16:99 
DOI 10.1186/s12877-016-0270-x
sake of meta-analyses, all data were treated as if from a
case–control study- where sarcopenia was considered as
the case and alcohol consumption represented the ex-
posure. Participants who were included in those studies
were people over 65 years of age who lived primarily in
their own homes in the community. Ethical approval
and consent from participants were declared in all the
studies which were analyzed.
Search methods for identification of studies
A 2-stage systematic review of the literature was used to
identify appropriate papers. Stage 1 involved searches of
four electronic databases: PubMed, Web of Knowledge,
EBSCO and Sciencedirect. The same search stream was
used in all databases (Table 1). Stage 2 involved examin-
ing cited references of relevant studies and review papers
identified during stage 1.
Data collection and analysis
All full-text articles were systematically examined for in-
clusion or exclusion. The primary criterion for including
the studies in the meta-analyses was that they transpar-
ently presented data regarding alcohol consumption by
both sarcopenic and nonsarcpenic individuals. Papers
containing duplicate data from a sample of participants
were excluded so that data from individual participants
was used only once. Acquired outcome and exposure
data were dichotomized with the counts for the two
variable categories entered into 2 × 2 contingency tables.
In some studies, where the sarcopenic status was divided
into three categories - non sarcopenia, moderate sarco-
penia and severe sarcopenia - the dual model was used;
non sarcopenia and sarcopenia. Alcohol consumption
was described inconsistently in studies. So individuals
were classified as exposed if they consumed alcohol re-
gardless the period or intensity of alcohol drinking.
Measures of effect sizes
As previously stated, our meta-analysis was based on
OR. The Cochran-Mantel-Haenszel statistical method
[7] and DerSimonian and Laird random-effects model
[8] were used to calculate OR. The Cochran-Mantel-
Haenszel statistical method is based on fixed-model effect
values of larger studies in contrast with DerSimonian and
Laird random-effects model, which gives relatively the
same weight to all the studies in the sample [9]. A test for
overall effect and a test for overall average effect for ran-
dom effects meta-analysis were used to choose which
model was better to apply. Additionally, we tested hetero-
geneity to find out if consolidated studies were consistent
in their findings. The I2 index was used for this purpose.
A rough guide to interpretation of I2 is as follows: 0 to
40 %: might not be important; 30 to 60 %: may represent
moderate heterogeneity; 50 to 90 %: may represent sub-
stantial heterogeneity; 75 to 100 %: considerable hetero-
geneity [10]. Funnel plots were used for visualizing biases.
A funnel plot is a simple scatter plot of the exposure effect
estimated from individual studies against some measures
of each study’s size or precision [6]. Furthermore, we con-
ducted a sensitivity analysis. That analysis involved remov-
ing and returning particular studies to determine the best
OR estimate taking into account heterogeneity and the ro-
bustness of conclusions. Statistics were carried out in the
Review Manager 5.3. Additionally, the illustrative com-
parative risks were calculated and they were presented in
summary of findings table. GRADEprofiler was used to
create and manage the summary of findings table.
Results
Description of studies
Figure 1 summarizes the yield of the search process. Of
214 papers identified as potentially relevant by the database
searching, 9 were included. An additional 4 papers identi-
fied through article reference lists were added. Ultimately,
therefore, 13 studies were included in the meta-analyses.
The main characteristics of the included studies are pre-
sented in Table 2. Data from 13,155 participants were ana-
lyzed; these included 5664 males and 7491 females. There
was a huge difference in the age of participants in the stud-
ies. The mean age ranged from 68.1 (SD = 0.6) years old to
83.8 (SD = 5.9) years old. The prevalence of sarcopenia
ranged from 3.8 to 27.2 % and the prevalence of alcohol
drinkers extended from 1.2 to 74.6 %.
Summary of the outcomes
The OR (95 % CI) in the fixed effect model for males
(Fig. 2) was 0.67 (0.54–0.83); the overall effect was Z
(6) = 3.67 (p = 0.0002), which was statistically significant.
Table 1 Search strings employed and yield associated with
searches of four electronic databases
Database (yield) Search terms
PubMed Search (sarcopenia [Title] OR “low muscle
mass” [Title] OR “lean body mass” [Title] OR
“skeletal muscle mass” [Title]) AND (alcohol*
OR “alcohol drink*” OR “alcohol consumption”
OR ethanol)
Web of Knowledge TITLE: (sarcopenia OR “low muscle mass” OR
“lean body mass” OR “skeletal muscle mass”)
AND TOPIC: (alcohol* OR “alcohol drink*” OR
“alcohol consumption” OR ethanol)
EBSCO TI (sarcopenia OR “low muscle mass” OR “lean
body mass” OR “skeletal muscle mass”) AND
TX (alcohol* OR “alcohol drink*” OR “alcohol
consumption” OR ethanol)
Sciencedirect TITLE (sarcopenia OR “low muscle mass” OR
“lean body mass” OR “skeletal muscle mass”)
and (alcohol* OR “alcohol drink*” OR “alcohol
consumption” OR ethanol)
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Fig. 1 Flow chart indicating how the final sample of papers included in the meta-analysis was established
Table 2 Characteristics of studies included in the meta-analyses
Study Designa Principal Aims
Akune et al. 2013 [21] Cross-sectional Investigate the prevalence of sarcopenia using the EWGSOP definition, and
clarified the association of sarcopenia with physical performance
Castillo et al. 2003 [23] Cohort Examine sarcopenia prevalence and risk factors in community-dwelling men
and women who attended a 1988–1992 Rancho Bernardo Study clinic visit
Domiciano et al. 2013 [11] Cohort Evaluate the prevalence and risk factors associated with sarcopenia,
according to these two criteria in community-dwelling older women
Figueiredo et al. 2013 [27] Cohort Evaluate the prevalence and risk factors associated with sarcopenia,
based on these two criteria
Landi et al. 2013 [24] Cohort Evaluate the impact of sarcopenia on the risk of all-cause death in a
population of frail older persons
Lau et al. 2005 [13] Cross-sectional Evaluate the prevalence of and risk factors for sarcopenia in elderly Chinese,
and to compare these observations with those in white persons
Lin et al. 2013 [28] Cross-sectional Determine the prevalence of sarcopenia using the EWGSOP algorithm
in a general elderly population in a Taiwanese metropolitan area
Liu et al. 2014 [14] Cohort Evaluate the prevalence of sarcopenia and its associative clinical
characteristics
Park et al. 2014 [22] Cross-sectional Examine whether vitamin D deficiency was positively associated with
sarcopenia in a gender-specific manner in adults aged 50 years,
independent of other covariates and possible confounders, including
body composition, blood tests, including serum parathyroid hormone
(PTH) levels, dietary intake, and hormone replacement therapy in women
Sampaio et al. 2014 [29] Cross-sectional Examine whether arterial stiffness, measured by the cardio-ankle vascular
index (CAVI), is associated with skeletal muscle mass index (SMI) in
Japanese community-dwelling older adults.
Silva Alexandre et al. 2014 [20] Cross-sectional Examine the prevalence and factors associated with sarcopenia in older
residents in São Paulo, Brazil
Volpato et al. 2014 [15] Cross-sectional Estimate the prevalence and investigate the clinical correlates of sarcopenia
Wu et al. 2014 [16] Cross-sectional Show the prevalence and associated factors of sarcopenia and severe
sarcopenia in rural communitydwelling older Taiwanese
aAs stated by the authors
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There was low heterogeneity (I2 = 0 %). For females the
OR (95 % CI) in the fixed effect model (Fig. 3) was 0.92
(0.75–1.11). The overall effect was not significant Z
(6) = 0.88 (p = 0.38); heterogeneity was moderate (I2 = 28 %).
In contrast with the females’ analysis, the model for the
overall population was robust. The OR (95 % CI) in the
fixed effect model (Fig. 4) was 0.78 (0.69–0.89), the
overall effect was Z (12) = 3.67 (p = 0.0002). Heterogen-
eity was moderate (I2 = 33 %). All the ORs were below
1, so the results suggest that alcohol consumption did
not contribute to the risk of sarcopenia.
Sensitivity analysis
A publication bias was not detected for data from al-
cohol drinking males. In addition, the results were
well-balanced. OR (95 % CI) with both models having
the same statistically significant value of 0.67 (0.54–
0.83). The only difference was in the tests for overall effect
using the fixed model, where Z (6) = 3.64 (p = 0.0003), and
the random effect model, where Z (6) = 3.67 (p = 0.0002).
Heterogeneity was low in both the cases (I2 = 0 %). In
contrast to males, the results in females’ analysis were not
as consistent. Heterogeneity was low; nevertheless, one
study-Domiciano et al. [11] was excluded due to publica-
tion bias. The most robust result was in the fixed effect
model after excluding that study. There the OR (95 % CI)
was 0.89 (0.73–1.08), which was not statistically signifi-
cant. Moreover, the test for the overall effect was very low
level Z (5) = 1.16 (p = 0.25), I2 = 0 %. In the overall
population, the fixed effect model excluding Domi-
ciano et al. [11] was the strongest, with Z (11) = 3.86
(p = 0.0001), I2 = 0 %. The OR (95 % CI) was 0.77
(0.68–0.88).
Summary of findings table
We used optimal ORs according to the sensitivity ana-
lyses to create a table summarizing the findings. The es-
timated risk of sarcopenia in the non-drinking males
group was 128 per 1000 and the corresponding risk in
the drinking males group was 89 per 1000 (95 % CI 73
to 108). The corresponding risk in medium risk popula-
tion was 92 per 1000 (95 % CI 76 to 112) in the drinking
males group. The estimated risk of sarcopenia in the
non-drinking females group was 111 per 1000 and the
corresponding risk in the drinking females group was
100 per 1000 (95 % CI 83 to 120). The corresponding
risk in medium risk population was 86 per 1000 (95 %
CI 72 to 104) in the drinking females group. The esti-
mated risk in the non-drinking overall population was
122 per 1000 and the corresponding risk in the drinking
females was 96 per 1000 (95 % CI 85 to 109). The corre-
sponding risk in medium risk population was 93 per
Fig. 2 The forest plot of effect sizes for alcohol drinking males
Fig. 3 The forest plot of effect sizes for alcohol drinking females
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1000 (95 % CI 82 to 105) the drinking overall popula-
tion. The non-drinking group always had a higher pro-
portion of people who were sarcopenic and excepting
females the finding was statistically significant. Those
analyses did not confirm that alcohol drinking is a risk
factor for sarcopenia development; quite the opposite.
Discussion
The results of the meta-analyses show that alcohol
drinking did not contribute to sarcopenia development.
The proportion of people categorized as sarcopenic was
less, albeit not always significantly, in alcohol drinking
group in all the analyses. This finding was strengthened
by sensitivity analysis. Our findings notwithstanding,
there were several problems encountered in the meta-
analysis.
There were huge ambiguities in scientific approaches
across the studies, for example, in diagnosing sarcopenia.
Currently the EWGSOP algorithm [12] is considered the
best tool for diagnosing sarcopenia. For the purposes of
this meta-analyses, the EWGSOP algorithm and muscle
mass measurement by dual-energy X-ray absorptiometry
(DEXA) or bioelectrical impedance analysis (BIA) were
considered suitable methods of sarcopenia diagnosis.
Even though the EWGSOP has established cut off points
for DEXA determined appendicular skeletal muscle mass
(ASM) (i.e., 7.26 kg/m2 for men and 5.5 kg/m2 for
women) and skeletal muscle index (SMI) (i.e., 7.23 or
7.25 kg/m2 for men and 5.67 kg/m2 for women), differ-
ent cut off points for ASM or SMI were used in almost
every study. For example, for males SMI cut off points
of <5.72 kg/m2 [13] and <7.0 kg/m2 [14] were used [13, 14],
for females cut off points of <4.82 kg/m2 < 5.9 kg/m2
were used [13, 14]. The EWGSOP has also established
cut off points for muscle mass determined by BIA.
Nevertheless, the SMIs cut off points used in the arti-
cles included in this review varied considerably. The
SMI cut off points for males ranged from <7.0 kg/m2
[10] to <8.82 kg/m2 [15]; for females they ranged
from <5.67 kg/m2 [16] to <6.42 kg/m2 [15]. This may
be one reason the prevalence of sarcopenia varied so
widely- from 3.8 % in the study by Domiciano et al.
[11] to 27.2 % in the study by Lau et al. [13].
Variability and a lack of objectivity in the description
of alcohol exposure might also have affected our re-
sults. It was almost impossible to find precise cumula-
tive data such as a total number of alcohol units over
time (e.g., drink-years). Exposure status was described
using incompatible categories according to the daily
amount, exposure period in the subjects’ lifetimes or
current habits. Therefore, it was difficult in this work
to find and establish an optimal stratification for expos-
ure. In any event, all approaches were based on the
subjective summarization by the participants. Although
in recent years self-reports has been shown repeatedly
to have good concordance with other methods [17],
they can be influenced by deliberate under- or overesti-
mation of consumption and by failures of memory and
other cognitive factors [18]. Nevertheless, some suitable
methods have been created previously, for example, the
alcohol use disorders identification test (AUDIT) [19],
following the recommendations of the World Health
Organization (WHO). Unfortunately, AUDIT does not
divide people into the categories of drinkers and non-
drinkers. Anyway, the subjective component of alcohol
exposure probably contributed to the huge variability of
percentage of alcohol drinkers described in individual
studies.
Despite problems with diagnosing sarcopenia and as-
certaining exposure we detected a statistically significant
Fig. 4 The forest plot of effect sizes for alcohol drinking overall population
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age-difference between sarcopenia and no sarcopenia
groups. That difference could work as important con-
founder of results. Aging is known to play a significant
role in sarcopenia development. The mean age differed
by more than 5 years in some of the studies we included.
Such a difference existed in males studied by Liu et al.
[14] and Silva Alexandre et al. [20], in females studied
by Akune et al. [21] and Silva Alexandre et al. [15], and
in the overall population studied Volpato et al. [15] and
Wu et al. [16].
Beyond the aforementioned limitations, we must note
that no study we examined had a primary focus on the
relationship between sarcopenia and alcohol consump-
tion. In all studies, alcohol consumption was merely one
of many observed variables. Also, the exclusion and in-
clusion criteria varied between studies and resulted in
the elimination of participants with characteristics which
could be interesting to explore. Among individuals ex-
cluded from participation in different studies were those
with poor functional status or metal implants [14] and
those with limb edema, a pacemaker, joint prosthesis, or
severe varicosities [15]. Other studies excluded older
adults who answered yes for the question “Do you cur-
rently have kidney failure?” [22] or who were unable to
perform the handgrip strength test or the walking por-
tion of the Short Physical Performance Battery (SPPB),
or who were unable to stand for measurement of weight
and height [20]. Some of these exclusions might not be
necessary in the event that the main aim of study was to
explore the relation between sarcopenia and alcohol
consumption. There were thus excluded subjects who
were older, had less education, drank less, reported more
difficulties in activities of daily living (ADL) and in-
strumental activities of daily living (IADL), had more
sever hypertension, diabetes, lung disease, heart dis-
ease, stroke, falls, instances of hospitalization, a more
sedentary lifestyle, more cognitive impairment, under-
nutrition and risk for undernutrition according to the
Mini-nutritional assessment (MNA) [20]. Nevertheless,
the inclusion of those subjects in the meta-analysis could
confound the results. In contrast, exclusion criteria were
not an issue is some studies [13, 21, 23, 24]. All the data
from these studies were clustered into the analyses
without regard to whether participants were accepted
according to the same exclusion and inclusion cri-
teria. Therefore, the cluster of the included studies
could bring a little bit different results if the criteria
were the same for all of them.
We also need to note that our results may have been
influenced due to different design between cohort stud-
ies and cross-sectional studies. Excepting the results of
Castillo et al. [21], the results of individual cohort stud-
ies indicated that for the overall population alcohol con-
sumption might increase the risk of sarcopenia, which
was completely opposite to the results in cross-sectional
studies. However, the design of those studies was classi-
fied by their authors. We accepted their classifications in
good faith even though there could be some concerns
that the classifications might not have been exactly cor-
rect. Epidemiological studies can be truly cross-sectional
(present drinking and present sarcopenia), case control
(drinking history and present sarcopenia), or cohort
(present drinking and future sarcopenia). Moreover, out
of cohort studies we only used the data from baselines,
therefore they could be considered as case–control stud-
ies rather than cohort studies and as such they do pro-
vide a higher level of evidence than cross-sectional
studies. Consolidation of the two study designs could be
justified in this meta-analysis, because they both are ob-
servational studies and they all were based on a similar
approach in extracting information about alcohol con-
sumption and sarcopenia diagnostics.
The results of the study show that alcohol consump-
tion is not associated with sarcopenia development.
Boffetta and Garfinkel [25] came to a similar conclu-
sion regarding alcohol consumption and mortality and
coronary heart disease (CHD). There, moderate alcohol
intake had a protective effect on CHD mortality. Other
authors have partly confirmed the possible protective in-
fluence of alcohol consumption on CHD mortality [26].
To sum up, we found out that alcohol consumption
was not a risk factor for the development of sarcopenia,
even more, according to the results alcohol consumption
could have protective character against sarcopenia. This
does not mean, however, that the authors recommend
drinking alcohol to prevent any diseases.
Conclusion
The implications for research would be summarized into
three recommendations. First, it would be beneficial to
diagnose sarcopenia more specifically using age, gender
and ethnicity specific reference values. Second, valid
tools for quantifying exposure need to be developed and
employed. Finally, it would be useful to study groups
more similar according to the age. Those groups’ com-
parison would be much more meaningful.




Availability of data and materials
Not applicable: As a meta-analysis, the data gathered
from other sources may or may not be publicly available
or in a repository.
Steffl et al. BMC Geriatrics  (2016) 16:99 Page 6 of 7
Abbreviations
ADL: activities of daily living; ASM: appendicular skeletal muscle mass;
AUDIT: alcohol use disorders identification test; BIA: bioelectrical impedance
analysis; CHD: coronary heart disease; DEXA: dual-energy X-ray absorptiometry;
EWGSOP: European working group on sarcopenia in older people;
IADL: instrumental activities of daily living; MNA: mini-nutritional
assessment; OR: odds ratio; SMI: skeletal muscle index; SPPB: short
physical performance battery; WHO: World Health Organization.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
MS made substantial contributions to analysis and interpretation of the data
RWB conceived the study, and participated in its design and helped to draft
the manuscript MP participated in the design of the study and the 2-stage
systematic review of the literature EK participated in the 2-stage systematic
review of the literature and helped to draft the manuscript IH participated in
the design of the study and drafted the manuscript. All the authors have
read and approved the final version of the manuscript.
Acknowledgements
This publication was supported by PRVOUK P20 and the research project 15-
32942A-P09 AZV of the Ministry of Health "Case management as a complex
intervention in patients with dementia" and project P 38.
Author details
1Department of Physiology and Biochemistry, Faculty of Physical Education
and Sport, Charles University Prague, Prague, Czech Republic. 2Department
of Physical Therapy, College of Pharmacy and Health Sciences, Campbell
University, Buies Creek, NC, USA. 3Centre of Gerontology, Faculty of
Humanities, Charles University Prague, Prague, Czech Republic.
Received: 28 August 2015 Accepted: 29 April 2016
References
1. Cruz-Jentoft AJ, Landi F, Schneider SM, Zúñiga C, Arai H, Boirie Y, et al.
Prevalence of and interventions for sarcopenia in ageing adults: a
systematic review. Report of the International Sarcopenia Initiative (EWGSOP
and IWGS). Age Ageing. 2014;43(6):748–59. doi:10.1093/ageing/afu115.
2. Visser M, Schaap LA. Consequences of sarcopenia. Clin Geriatr Med. 2011;
27(3):387–99. doi:10.1016/j.cger.2011.03.006.
3. Forsyth CB, Voigt RM, Keshavarzian A. Intestinal CYP2E1: A mediator of
alcohol-induced gut leakiness. Redox Biol. 2014;3:40–6. doi:10.1016/j.redox.
2014.10.002.
4. Thapaliya S, Runkana A, McMullen MR, Nagy LE, McDonald C, Naga Prasad
SV, et al. Alcohol-induced autophagy contributes to loss in skeletal muscle
mass. Autophagy. 2014;10(4):677–90. doi:10.4161/auto.27918.
5. Thomas DR. Loss of skeletal muscle mass in aging: examining the
relationship of starvation, sarcopenia and cachexia. Clin Nutr. 2007;26:
389–99. doi:10.1016/j.clnu.2007.03.008.
6. Higgins J, Green S. In: Higgins J, Green S, editors. Cochrane handbook for
systematic reviews of interventions version 5.1.0. 2011. http://handbook.
cochrane.org/. Accessed March 2011.
7. Mantel N, Haenszel W. Statistical aspects of the analysis of data from
retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48. doi:10.
1093/jnci/22.4.719.
8. DerSimonian R, Kacker R. Random-effects model for meta-analysis of clinical
trials: an update. Contemp Clin Trials. 2007;28:105–14. doi:10.1016/j.cct.2006.
04.004.
9. Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. Introduction to
meta-analysis. Chichester: John Wiley & Sons, Ltd; 2009. doi:10.1002/
9780470743386.fmatter.
10. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in
meta-analyses. BMJ. 2003;327:557–60. doi:10.1136/bmj.327.7414.557.
11. Domiciano DS, Figueiredo CP, Lopes JB, Caparbo VF, Takayama L, Menezes
PR, et al. Discriminating sarcopenia in community-dwelling older women
with high frequency of overweight/obesity: the Sao Paulo Ageing & Health
Study (SPAH). Osteoporos Int. 2013;24(2):595–603. doi:10.1007/s00198-012-
2002-1.
12. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, et al.
Sarcopenia: European consensus on definition and diagnosis: Report of the
European Working Group on Sarcopenia in Older People. Age Ageing. 2010;
39(4):412–23. doi:10.1093/ageing/afq034.
13. Lau EM, Lynn HS, Woo JW, Kwok TC, Melton 3rd LJ. Prevalence of and risk
factors for sarcopenia in elderly Chinese men and women. J Gerontol A Biol
Sci Med Sci. 2005;60(2):213–6.
14. Liu LK, Lee WJ, Chen LY, Hwang AC, Lin MH, Peng LN, et al. Sarcopenia, and
its association with cardiometabolic and functional characteristics in Taiwan:
Results from I- Lan Longitudinal Aging Study. Geriatr Gerontol Int. 2014;14
Suppl 1:36–45. doi:10.1111/ggi.12208.
15. Volpato S, Bianchi L, Cherubini A, Landi F, Maggio M, Savino E, et al.
Prevalence and Clinical Correlates of Sarcopenia in Community-Dwelling
Older People: Application of the EWGSOP Definition and Diagnostic
Algorithm. J Gerontol A Biol Sci Med Sci. 2014;69(4):438–46. doi:10.1093/
gerona/glt149.
16. Wu CH, Chen KT, Hou MT, Chang YF, Chang CS, Liu PY, et al. Prevalence
and associated factors of sarcopenia and severe sarcopenia in older
Taiwanese living in rural community: The Tianliao Old People study 04.
Geriatr Gerontol Int. 2014;14 Suppl 1:69–75. doi:10.1111/ggi.12233.
17. Del Boca FK, Darkes J. The validity of self-reports of alcohol consumption: state
of the science and challenges for research. Addiction. 2003;98 Suppl 2:1–12.
18. Babor TF, Steinberg K, Anton R, Del Boca F. Talk is cheap: measuring
drinking outcomes in clinical trials. J Stud Alcohol. 2000;61(1):55–63.
19. Saunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M. Development
of the alcohol use disorders identification test (AUDIT): WHO collaborative
project on early detection of persons with harmful alcohol consumption.
Addiction. 1993;88(6):791–804.
20. Silva Alexandre T, Oliveira Duarte YA, Santos JLF, Wong R, Lebrão ML.
Prevalence and associated factors of sarcopenia among elderly in Brazil:
Findings from the SABE study. J Nutr Health Aging. 2014;18(3):284–90. doi:
10.1007/s12603-013-0413-0.
21. Akune T, Muraki S, Oka H, Tanaka S, Kawaguchi H, Nakamura K, et al.
Exercise habits during middle age are associated with lower prevalence of
sarcopenia: the ROAD study. Osteoporos Int. 2014;25(3):1081–8. doi:10.1007/
s00198-013-2550-z.
22. Park S, Ham JO, Lee BK. A positive association of vitamin D deficiency and
sarcopenia in 50 year old women, but not men. Clin Nutr. 2014;33(5):900–5.
doi:10.1016/j.clnu.2013.09.016.
23. Castillo EM, Goodman-Gruen D, Kritz-Silverstein D, Morton DJ, Wingard DL,
Barrett-Connor E. Sarcopenia in elderly men and women: The Rancho
Bernardo study. Am J Prev Med. 2003;25(3):226–31.
24. Landi F, Liperoti R, Russo A, Giovannini S, Tosato M, Capoluongo E, et al.
Sarcopenia as a risk factor for falls in elderly individuals: Results from the
ilSIRENTE study. Clin Nutr. 2012;31(5):652–8. doi:10.1016/j.clnu.2012.02.007.
25. Boffetta P, Garfinkel L. Alcohol drinking and mortality among men enrolled
in an American Cancer Society prospective study. Epidemiology. 1990;1(5):
342–8.
26. Kannel WB, Ellison RC. Alcohol and coronary heart disease: the evidence for
a protective effect. Clin Chim Acta. 1996;246(1–2):59–76.
27. Figueiredo CP, Domiciano DS, Lopes JB, Caparbo VF, Scazufca M, Bonfa E, et al.
Prevalence of sarcopenia and associated risk factors by two diagnostic criteria
in community-dwelling older men: the Sao Paulo Ageing & Health Study
(SPAH). Osteoporos Int. 2014;25(2):589–96. doi:10.1007/s00198-013-2455-x.
28. Lin CC, Lin WY, Meng NH, Li CI, Liu CS, Lin CH, et al. Sarcopenia
prevalence and associated factors in an elderly Taiwanese metropolitan
population. J Am Geriatr Soc. 2013;61(3):459–62. doi:10.1111/jgs.12129.
29. Sampaio RA, Sewo Sampaio PY, Yamada M, Yukutake T, Uchida MC,
Tsuboyama T, et al. Arterial stiffness is associated with low skeletal muscle
mass in Japanese community-dwelling older adults. Geriatr Gerontol Int.
2014;14 Suppl 1:109–14. doi:10.1111/ggi.12206.
Steffl et al. BMC Geriatrics  (2016) 16:99 Page 7 of 7
